17,261 trials
Thyroid Cancer
Primary: Objective Response Rate (ORR) — 50.0; 35.6 Percentage of participants
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure (IOP) — 24.1; 23.6; 13.9; 16.9 mmHg — p=0.001
Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Primary: Relative Bioavailability of Tiotropium With GSP304 in Comparison to SPIRIVA RESPIMAT 5 μg Based on CmaxSS — 4.10; 8.00; 21.80; 14.00 pg/mL
Cardiac Arrest · Metabolic Acidosis
Primary: Return of Spontaneous Circulation (ROSC) — 4; 16 ROSC percents of each group
Lupus Erythematosus, Systemic
Primary: Number of Particpants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 170; 50 Participants
Glioblastoma · Cancer of Brain and Nervous System · Glioblastoma Multiforme
Primary: Number of Dose-limiting Toxicities (DLTs) — 0; 0; 0; 1 Number of DLT observed
Neuroblastoma
Primary: Maximum Tolerated Dose (MTD) When Given Together With Fixed Doses of Irinotecan and Temozolomide in Children and Young Adults With Relapsed or Refractory Neuroblastoma…
Myeloproliferative Diseases
Primary: Participants With Objective Response — 7 Participants
Breast Cancer
Primary: Phase I Cohort A: Maximum Tolerated AZD0530 Daily Dose Used in Combination With Daily Oral Anastrozole — 1; 175 mg/day oral dose
Alzheimer's Disease
Primary: Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI) — 0.621528; 0.6447692; 0.654822667; 0.579838667 ml/110g/min
Atopic Dermatitis
Primary: Number of Patients With Treatment Emergent Adverse Events (TEAEs) — 3; 6 Participants
Glucose Intolerance · Type 2 Diabetes Mellitus · Metabolic Syndrome
Primary: Chang in Disposition Index, a Measure of Beta Cell Function — 287; 314; -122; -129 units on a scale
Prostate Cancer
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE) or Serious Adverse Events (SAE) — 6; 8; 23; 5 participants
Adrenocortical Carcinoma · Peritoneal Carcinomatosis
Primary: Intraperitoneal Progression Free Survival (PFS) — 19 Months
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients